Bimatoprost + Timolol

Thông tin thuốc gốc
Chỉ định và Liều dùng
Ocular hypertension, Open-angle glaucoma
Adult: In patients who are insufficiently responsive to topical β-blockers or prostaglandin analogues: Each mL of soln contains bimatoprost 0.3 mg and timolol 5 mg: Instill 1 drop in the affected eye(s) once daily, either in the morning or in the evening at the same time each day.
Chống chỉ định
Reactive airway disease including bronchial asthma or history of bronchial asthma, severe COPD; sinus bradycardia, sick sinus syndrome, SA block, 2nd or 3rd degree AV block, not controlled w/ pacemaker; overt cardiac failure, cardiogenic shock.
Thận trọng
Patient w/ CV diseases (e.g. CHD, Prinzmetal’s angina, cardiac failure), hypotension therapy w/ β-blockers; severe peripheral circulatory disturbance/disorders (i.e. severe forms of Raynaud's disease/syndrome); mild to moderate COPD; patient subject to spontaneous hypoglycaemia or to patient w/ labile diabetes; corneal diseases. Hepatic or renal impairment. Pregnancy and lactation.
Phản ứng phụ
Headache, dizziness; conjunctival hyperaemia, superficial punctuate keratitis, corneal erosion, burning sensation, eye pruritus, dryness, pain, discharge, and irritation, stinging sensation in the eye, foreign body sensation in the eye, foreign body sensation, eyelid erythema, pruritus, and oedema, photophobia, visual disturbance, visual acuity worsened, blepharitis, epiphora, growth of eyelashes; rhinitis, blepharal pigmentation, hirsutism, periocular skin hyperpigmentation.
Thông tin tư vấn bệnh nhân
This drug may cause transient blurred vision, if affected, do not drive or operate machinery.
Tương tác
Additive effects resulting in hypotension and/or marked bradycardia w/ oral Ca channel blockers, guanethidine, β-blockers, parasympathomimetics, anti-arrhythmics, digitalis glycosides. Potentiation of systemic β-blockade (e.g. decreased heart rate, depression) w/ CYP2D6 inhibitors (e.g. quinidine, fluoxetine, paroxetine). Combination w/ epinephrine may cause mydriasis.
Tác dụng
Description: Bimatoprost is a synthetic prostamide structurally related to prostaglandin F which reduces intraocular pressure (IOP) by increasing aqueous humour outflow through the trabecular meshwork and enhancing uveoscleral outflow. Timolol is a β1 and β2 non-selective adrenergic receptor blocking agent which lowers IOP by reducing aqueous humour formation. Bimatoprost and timolol decrease elevated IOP by complementary mechanisms of action and the combined effect results in additional IOP reduction compared to either compd administered alone.
Absorption: Bimatoprost: Small amounts are absorbed (ophth). Time to peak plasma concentration: W/in 10 min. Timolol: Time to peak plasma concentration: Approx 1-2 hr.
Distribution: Bimatoprost: Moderately distributed into body tissues. Volume of distribution: 0.67 L/kg. Plasma protein binding: Approx 88%.
Metabolism: Bimatoprost: Undergoes oxidation, de-ethylation and glucuronidation. Timolol: Undergoes partial hepatic metabolism.
Excretion: Bimatoprost: Mainly via urine (up to 67%); faeces (approx 25%). Elimination half-life: 45 min. Timolol: Via urine as unchanged drug and metabolites. Plasma half-life: Approx 4-6 hr.
Đặc tính

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Bimatoprost, CID=5311027, (accessed on Jan. 21, 2020)

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Timolol, CID=33624, (accessed on Jan. 21, 2020)

Phân loại MIMS
Buckingham R (ed). Bimatoprost. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 04/03/2016.

Buckingham R (ed). Timolol Maleate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 04/03/2016.

Joint Formulary Committee. Bimatoprost with Timolol. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 04/03/2016.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Bimatoprost + Timolol từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2021 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi
  • Bimat-T
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in